- Home
- MUR vs LNTH Comparison
MUR vs LNTH Comparison
Compare MUR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | LNTH |
|---|---|---|
| Founded | 1950 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.9B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MUR | LNTH |
|---|---|---|
| Price | $34.01 | $82.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 6 |
| Target Price | $29.29 | ★ $83.20 |
| AVG Volume (30 Days) | ★ 1.9M | 987.7K |
| Earning Date | 04-27-2026 | 05-25-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.72 | ★ 3.41 |
| Revenue | ★ $2,718,823,000.00 | $343,374,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.67 | $13.47 |
| P/E Ratio | $45.32 | ★ $24.38 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $18.95 | $47.27 |
| 52 Week High | $36.08 | $108.86 |
Technical Indicators
Market Signals| Indicator | MUR | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 69.26 |
| Support Level | $29.81 | $77.38 |
| Resistance Level | $34.40 | $83.53 |
| Average True Range (ATR) | 1.39 | 3.40 |
| MACD | 0.01 | 0.60 |
| Stochastic Oscillator | 65.03 | 84.63 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.